Dendreon

Jon Jon is the CEO of Dendreon.

The decision makers in Dendreon are Michael Allen, Alexis Jason, Bruce Johnson, etc. Click to Find Dendreon decision makers emails.

Dendreon's flagship product is PROVENGE (sipuleucel-T), which is an FDA-approved immunotherapy designed for the treatment of prostate cancer. It works by using a patient's own immune cells to target and attack cancer cells. The process involves collecting the patient's immune cells, modifying them to recognize prostate cancer cells, and then infusing them back into the patient. This personalized approach aims to enhance the body's natural immune response against cancer.

Dendreon primarily focuses on treating prostate cancer through its innovative immunotherapy solutions. While its flagship product, PROVENGE, is specifically approved for metastatic castrate-resistant prostate cancer, the company is also involved in research and development efforts that may expand its offerings to other types of cancers in the future.

Dendreon offers contract manufacturing services to support the production of cellular therapies. This includes the development and manufacturing of personalized immunotherapies for other companies in the biopharmaceutical industry. Dendreon's expertise in cellular immunotherapy and its state-of-the-art facilities enable it to provide high-quality manufacturing solutions that meet regulatory standards and support the advancement of innovative cancer treatments.

Dendreon adheres to strict regulatory guidelines and quality assurance protocols to ensure the safety and efficacy of its products. This includes compliance with Good Manufacturing Practices (GMP) and rigorous testing throughout the production process. The company conducts extensive clinical trials to evaluate the safety and effectiveness of its therapies, and it continuously monitors product performance post-approval to maintain high standards of patient care.

Dendreon is committed to supporting healthcare professionals and patients through educational resources, treatment guidance, and access to clinical information about its therapies. The company provides comprehensive training for healthcare providers to ensure they understand the administration and benefits of PROVENGE. Additionally, Dendreon offers resources for patients to help them navigate their treatment options and understand the immunotherapy process.

Dendreon is actively engaged in research and development to advance the field of immunotherapy. The company is exploring new applications of its cellular immunotherapy technology, including potential treatments for other types of cancer. Dendreon is also investigating combination therapies that may enhance the effectiveness of its existing products. By leveraging its expertise in immunotherapy, Dendreon aims to contribute to the ongoing evolution of cancer treatment and improve patient outcomes.